Gadolinium-based nanoparticles for theranostic MRI-radiosensitization

Nanomedicine

Volumn 10, Issue 11, 2015, Pages 1801-1815

  Lux, François ^a   Sancey, Lucie ^a   Bianchi, Andrea ^b   Crémillieux, Yannick ^b   Roux, Stéphane ^c   Tillement, Olivier ^a  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

gadolinium; MRI; multimodality; nanoparticles; oncology; radiotherapy; theranostic

Indexed keywords

GADODIAMIDE; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM NANOPARTICLE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GOLD NANOPARTICLE; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; CONTRAST MEDIUM;

CLINICAL EFFECTIVENESS; CRYSTALLIZATION; FLUORESCENCE IMAGING; HUMAN; IMAGE ANALYSIS; IONIZING RADIATION; IRRADIATION; MULTIMODAL IMAGING; NEUTRON CAPTURE THERAPY; NEUTRON RADIATION; NEUTRON THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; PHOTODYNAMIC THERAPY; PHOTON THERAPY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOLOGICAL PARAMETERS; RADIOSENSITIZATION; REVIEW; CHEMISTRY; NEOPLASMS; PATHOLOGY; PHOTOCHEMOTHERAPY; RADIOGRAPHY; THERANOSTIC NANOMEDICINE; TISSUE DISTRIBUTION;

CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; NEOPLASMS; PHOTOCHEMOTHERAPY; RADIATION-SENSITIZING AGENTS; THERANOSTIC NANOMEDICINE; TISSUE DISTRIBUTION;

EID: 84931846432     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.30     Document Type: Review

References (110)

1. Sanchez C, Belleville P, Popall M, Nicole L. Applications of advanced hybrid organic-inorganic nanomaterials: from laboratory to market. Chem. Soc. Rev. 40, 696-753 (2011).
2. Kim BH, Hackett MJ, Park J, Hyeon T. Synthesis, characterization, and application of ultrasmall nanoparticles. Chem. Mater. 26, 59-71 (2013).
3. Yang Z, Chen CY, Roy P, Chang HT. Quantum dotsensitized solar cells incorporating nanomaterials. Chem. Comm. 47, 9561-9571 (2011).
4. Yan L, Zheng YB, Zhao F et al. Chemistry and physics of a single atomic layer: strategies and challenges for functionalization of graphene and graphene-based materials. Chem. Soc. Rev. 41, 97-114 (2012).
5. Wang ZL, Zhu G, Yang Y, Wang S, Pan C. Progress in nanogenerators for portable electronics. Materials Today 15(12), 532-543 (2012).
6. Wu Y, Wang D, Li Y. Nanocrystals from solutions: catalysts. Chem. Soc. Rev. 43, 2112-2124 (2014).
7. Sozer N, Kokini J. Nanotechnology and its applications in the food sector. Trends Biotechnol. 27(2), 82-89 (2009).
8. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture of nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 9, 1-14 (2013).
9. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. 9, 615-627 (2010).
10. Hahn MA, Singh AK, Sharma P, Brown SC, Moudgil BM. Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives. Anal. Bioanal. Chem. 399, 3-27 (2011).
11. Kateb B, Chiu K, Black KL et al. Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? Neuroimage 54, S106-S124 (2011).
12. Liu Z, Kiessling F, Gätjens J. Advanced nanomaterials in multimodal imaging: design, functionnalization, and biomedical applications. J. Nano. Mat. 2010(ID 894303), 15 (2010).
13. Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem. Soc. Rev. 38, 1759-1782 (2009).
14. Schladt TD, Schneider K, Child H, Tremel W. Synthesis and bio-functionalization of magnetic nanoparticles for medical diagnosis and treatment. Dalton Trans. 40, 6315-6343 (2011).
15. Zrazhevskiy P, Sena M, Gao X. Designing multifunctional quantum dots for bioimaging, detection and drug delivery. Chem. Soc. Rev. 39, 4326-4354 (2010).
16. Lee DE, Koo H, Sun IC, Ryu JH, Kim K, Kwon IC. Multifunctionnal nanoparticles for multimodal imaging and theragnosis. Chem. Soc. Rev. 41, 2656-2672 (2012).
17. Huang WY, Davis JJ. Multimodality and nanoparticles in medical imaging. Dalton Trans. 40, 6087-6103 (2011).
18. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5(4), 505-515 (2008).
19. Faure AC, Dufort S, Josserand V et al. Control of the in vivo biodistribution of hybrid nanoparticles with different poly(ethyleneglycol) coatings. Small 5(22), 2565-2575 (2009).
20. Choi KY, Liu G, Lee S, Chen X. Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale 4, 330-342 (2012).
21. Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconj. Chem. 22, 1879-1903 (2011).
22. Shubayev VI, Pisanic II TR, Jin S. Magnetic nanoparticles for theragnostics. Adv. Drug. Deliv. Rev. 61, 467-477 (2009).
23. McCarthy JR, Weissleder R. Mulifunctional magnetic nanoparticles for targeted imaging and therapy. Adv. Drug. Deliv. Rev. 60, 1241-1251 (2008).
24. Zeng Y, Zhang D, Wu Y et al. Lipid-AuNps@PDA nanohybrid for MRI/CT imaging and photothermal therapy of hepatocellular carcinoma. ACS Appl. Mater. Interfaces 6, 14266-14277 (2014).
25. Montalti M, Prodi L, Rampazzo E, Zaccheroni N. Dyedoped silica nanoparticles as luminescent organized systems for nanomedicine. Chem. Soc. Rev. 43, 4243-4268 (2014).
26. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preparative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 63, 8122-8125 (2003).
27. De Rosales RTM. Potential clinical applications of bimodal PET-MRI or SPECT-MRI agents. J. Labelled Comp. Radiopharm. 57(4), 298-303 (2014).
28. Kryza D, Taleb J, Janier M et al. Biodistribution study of nanometric hybrid gadolinium oxide particles as a multimodal SPECT/MR/optical imaging and theragnostic agent. Bioconj. Chem. 22, 1145-1152 (2011).
29. Misri R, Saatchi K, Häfeli UO. Nanoprobes for hybrid SPECT/MR molecular imaging. Nanomedicine 7(5), 719-733 (2012).
30. Reddy LH, Arias JL, Nicolas J, Couvreur P. Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem. Rev. 112, 5818-5878 (2012).
31. Yang HW, Liu HL, Li ML et al. Magnetic gold-nanorod/ PNIPAAmMA nanoparticles for dual magnetic resonance and photoacoustic imaging and targeted photothermal therapy. Biomaterials 34, 5651-5660 (2013).
32. Vivero-Escoto JL, Huxfords-Phillips RC, Lin W. Silicabased nanoprobes for biomedical imaging and theranostic applications. Chem. Soc. Rev. 41, 2673-2685 (2012).
33. Le Duc G, Miladi I, Alric C et al. Towards an image-guided microbeam radiation therapy using gadolinium-based nanoparticles. ACS Nano 5, 9566-9574 (2011).
34. Dufort S, Bianchi A, Henry M et al. Nebulized gadoliniumbased nanoparticles: a theranostic approach for lung tumor imaging and radiosensitization. Small 11(2), 215-221 (2015).
35. Sancey L, Lux F, Kotb S et al. The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy. Br. J. Radiol. 87, 20140134 (2014).
36. Leibfarth S, Mönnich D, Welz S et al. A strategy for multimodal deformable image registration to integrate PET/ MR into radiotherapy treatment planning. Acta Oncol. 52, 1353-1359 (2013).
37. Van der Heide UA, Houweling AC, Groenendaal G, Beets-Tan RGH, Lambin P. Functional MRI for radiotherapy dose painting. Magn. Reson. Imaging 30, 1216-1223 (2012).
38. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys. Med. Biol. 49, N309-N315 (2004).
39. Butterworth KT, McMahon SJ, Taggart LE, Prise KM. Radiosensitization by gold nanoparticles: effective at megavoltage energies and potential role of oxidative stress. Transl. Cancer Res. 2(4), 269-279 (2013).
40. Kwatra D, Venugopal A, Anant S. Nanoparticles in radiation therapy: a summary of various approaches to enhance radiosensitization in cancer. Transl. Cancer Res. 2(4), 330-342 (2013).
41. Pradhan AK, Nahar SN, Montenegro M et al. Resonant x-ray Enhancement of the Auger effect in high-Z atoms, molecules, and nanoparticles: potential biomedical applications. J. Phys. Chem. A 119, 12356-12363 (2009).
42. Miladi I, Alric C, Dufort S et al. The In vivo radiosensitizing effect of gold nanoparticles based MRI constrast agents. Small 10(6), 1116-1124 (2014).
43. Butterworth K, McMahon SJ, Curell FJ, Prise KM. Physical basis and biological mechanisms of gold nanoparticles radiosensitization. Nanoscale 4(16), 4830-4838 (2012).
44. McMahon SJ, Hyland WB, Muir MF et al. Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles. Sci. Rep. 1(18), 1-9 (2011).
45. Sherry AD, Caravan P, Lenkinski RE. Primer on gadolinium chemistry. J. Magn. Reson. Imaging 30, 1240-1248 (2009).
46. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev. 99, 2293-2352 (1999).
47. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem. Soc. Rev. 35, 512-523 (2006).
48. Bulte JWM. The chemistry of contrast agents in medical magnetic resonance imaging. In: NMR in Biomedicine. Merbach AE, Toth E (Eds). Wiley, Chichester, UK, Volume 17, Issue 4, Page 210 (2001).
49. Geraldes FGC, Laurent S. Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast Media Mol. Imaging 4, 1-23 (2008).
50. Terreno E, Castelli DC, Viale A, Aime S. Challenges for molecular magnetic resonance imaging. Chem. Rev. 110, 3019-3042 (2010).
51. Li Y, Beija M, Laurent S et al. Macromolecular ligands for gadolinium MRI contrast agents. Macromolecules 45, 4196-4204 (2012).
52. Lim J, Turkbey B, Bernardo M et al. Gadolinium MRI contrast agents based on triazine dendrimers: relaxivity and in vivo pharmacokinetics. Bioconj. Chem. 23, 2291-2299 (2012).
53. Lux J, Chan M, Vander Elst L et al. Metal chelating crosslinkers form nanogels with high chelation stability. J. Mater. Chem. B 1, 6359-6364 (2013).
54. Ananta JS, Godin B, Sethi R et al. Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat. Nanotechnol. 5(11), 815-821 (2010).
55. Botta M, Tei L. Relaxivity enhancement in macromolecular and nanosized GdIII-based MRI contrast agents. Eur. J. Inorg. Chem. 12, 1945-1960 (2012).
56. Lux F, Roux S, Perriat P, Tillement O. Biomedical applications of nanomaterials containing gadolinium. Current Inorg. Chem. 1, 117-129 (2011).
57. Pietsch H, Jost G, Frenzel T et al. Efficacy and safety of lanthanoids as x-ray contrast agents. Eur. J. Radiol. 80(2), 349-356 (2011).
58. Preihs C, Arambula JF, Magda D et al. Recent developments in texaphyrin chemistry and drug discovery. Inorg. Chem. 52, 12184-12192 (2013).
59. Morrison DE, Aitken JB, de Jonge MD, Ioppolo JA, Harris HH, Rendina LM. High mitochondrial accumulation of new gadolinium(III) agents within tumour cells. Chem. Commun. 50, 2252-2254 (2014).
60. Bridot JL, Dayde D, Rivière C et al. Hybrid gadolinium oxide nanoparticles combining imaging and therapy. J. Mat. Chem. 19, 2328-2335 (2009).
61. Thomsen D. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur. Radiol. 16, 2619-2621 (2006).
62. Stasiuk GJ, Long NJ. The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging. Chem. Commun. 49, 2732-2746 (2013).
63. Davies GL, Kramberger I, Davies JJ. Environmentally responsive MRI contrast agents. Chem. Commun. 49, 9704-9721 (2013).
64. Shokrollahi H. Contrast agents for MRI. Mat. Sci. Eng. C 33, 4485-4497 (2013).
65. Choi HS, Liu W, Misra P et al. Renal clearance of quantum dots. Nat. Biotechnol. 25(10), 1165-1170 (2007).
66. Choi HS, Liu WH, Liu FB et al. Design considerations for tumour-targetednanoparticles. Nat. Nanotechnol. 5(1), 42-47 (2010).
67. Mignot A., Truillet C, Lux F et al. A top-down synthesis route to ultrasmall multifunctional Gd-based silica nanoparticles for theranostic applications. Chem. Eur. J. 19, 6122-6136 (2013).
68. Sancey L, Motto-Ros V, Busser B et al. Laser spectrometry for multi-elemental imaging of biological tissues. Sci. Rep. 4, 6065 (2014).
69. Bianchi A, Lux F, Tillement O, Crémillieux Y. High resolution contrast enhanced lung MRI in mice using ultra-short echo time radial imaging and intratracheally administrated Gdbased contrast agent. Mag. Res. Med. 70, 1419-1426 (2013).
70. Bianchi A, Dufort S, Lux F et al. Quantitative biodistribution and pharmacokinetics of multimodal gadolinium-based nanoparticles for lungs using ultrashort TE MRI. Magn. Reson. Mater. Phy. 27(4), 303-316 (2014).
71. Bianchi A, Dufort S, Lux F et al. Targeting and in vivo imaging of non-small-cell lung cancer using nebulized multimodal contrast agents. Proc Natl Acad. Sci. USA 111(25), 9247-9252 (2014).
72. Pagel MD. The hope and hype of multimodality imaging contrast agents. Nanomedicine 6(6), 945-948 (2011).
73. Louie A. Multimodality imaging probes: design and challenges. Chem. Rev. 110, 3146-3195 (2010).
74. Cormode DP, Sanchez-Gaytan BL, Mieszawska AJ, Fayad ZA, Mulder WJM. Inorganic nanocrystals as contrast agents in MRI: synthesis, coating and introduction of multifunctionnality. NMR Biomed. 26, 766-780 (2013).
75. Alric C, Taleb J, Le Duc G et al. Gadolinium chelate coated nanoparticles as contrast agents for both x-ray computed tomography and magnetic resonance imaging. J. Am. Chem. Soc. 130(18), 5908-5915 (2008).
76. Alric C, Miladi I, Kryza D et al. The biodistribution of gold nanoparticles designed for renal clearance. Nanoscale 5, 5930-5939 (2013).
77. Park J, Bhuniya S, Lee H et al. A DTTA-ligated uridinequantum dot conjugate as a bimodal contrast agent for cellular imaging. Chem. Commun. 48, 3218-3220 (2012).
78. Lin B, Yao X, Zhu Y, Shen J, Yang X, Li C. Multifunctionnal gadolinium-labelled silica-coated core/shell quantum dots for magnetic resonance imaging of cancer cells. RSC Adv. 4, 20641-20648 (2014).
79. Lux F, Mignot A, Mowat P et al. Ultrasmall rigid platforms as multimodal probes for medical applications. Angew. Chem. Int. Ed. Engl. 51, 12299-13303 (2011).
80. Benachour H, Bastogne T, Toussaint M et al. Real-time monitoring of photocytotoxicity in nanoparticles-based photodynamic therapy: a model-based approach. PLoS ONE 7(11), e48617 (2012).
81. Truillet C, Lux F, Moreau J et al. Bifunctionnal polypyridyl-Ru(II) complex grafted onto gadolinium-based nanoparticles for MR-imaging and photodynamic therapy. Dalton Trans. 42, 12410-12420 (2013).
82. Benachour H, Sève A, Bastogne T et al. multifunctionnal peptide-conjugated hybrid silica nanoparticles for photodynamic therapy and MRI. Theranostics 2(9), 889-904 (2012).
83. Roberts D, Zhu WL, Frommen CM, Rosenzweig Z. Synthesis of gadolinium oxide magnetoliposomes for magnetic resonance imaging. J. App. Phys. 87(9), 6208-6210 (2000).
84. McDonald MA, Watkin KL. Small particulate gadolinium oxide albumin microspheres as multimodal contrast and therapeutic agents. Investig. Radiol. 38(6), 305-310 (2003).
85. Bazzi R, Flores MA, Louis C et al. Synthesis and properties of europium-based phosphors on the nanometer scale: Eu2O3, Gd2O3:Eu and Y2O3:Eu. J. Colloid Interface Sci. 273, 191-197 (2004).
86. Louis C, Bazzi R, Marquette CA et al. Nanosized hybrid particles with double luminescence for biological labelling. Chem. Mater. 17, 1673-1682 (2005).
87. Bridot JL, Faure AC, Laurent S et al. Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. J. Am. Chem. Soc. 129, 5076-5084 (2007).
88. Engstrom M, Klasson A, Pedersen H, Vahlberg C, Kall PO, Uvdal K. High proton relaxivity for gadolinium oxide nanoparticles. Magn. Reson. Mater. Phys. 19, 180-186 (2006).
89. Fang J, Chandrasekharan P, Liu XL et al. Manipulating the surface coating of ultra-small Gd2O3 nanoparticles for improved T-1-weighted MR imaging. Biomaterials 35(5), 1632-1642 (2014).
90. Evanics E, Diamente PR, van Veggel FCJM, Stanisz GJ, Prosser RS. Water-soluble GdF3 and GdF3/LaF3 nanoparticles-physical characterization and NMR relaxation properties. Chem. Mater. 18, 2499-2505 (2006).
91. Johnson NJJ, Oakden W, Stanisz GJ, Prosser RS, van Veggel FCJM. Size-tunable, ultrasmall NaGdF4 nanoparticles: insights into their T1 MRI contrast enhancement. Chem. Mater. 23, 3714-3722 (2011).
92. Liang G, Cao L, Chen H et al. Ultrasmall gadolinium hydrated carbonate nanoparticle: an advanced T1 MRI contrast agent with large longitudinal relaxivity. J. Mat. Chem. B 1, 629-638 (2013).
93. Chen F, Zhang S, Bu W et al. A uniform sub-50 nm-sized magnetic/upconversion fluorescent bimodal imaging agent capable of generating singlet oxygen by using a 980 nm laser. Chem. Eur. J. 18, 7082-7090 (2012).
94. Zhou J, Yu M, Sun Y et al. Fluorine-18-labeled Gd3+/Yb3+/ Er3+ co-doped NaYF4 nanophosphors for multimodality PET/MR/UCL imaging. Biomaterials 32, 1148-1156 (2011).
95. Xiao Q, Zheng X, Bu W et al. A core/satellite multifunctionnal nanotheranostic for in vivo imaging and tumor eradication by tadiation/photothermal synergistic therapy. J. Am. Chem. Soc. 135, 13041-13048 (2013).
96. Dumont MF, Hoffman HA, Yoon PRS et al. Biofunctionnalized gadolinium-containing prussian blue nanoparticles as multimodal molecular imaging agents. Bioconj. Chem. 25, 129-137 (2014).
97. Locher GL. Biological effects and therapeutic possibilities of neutrons. Am. J. Roentgenol. Radium Ther. 36, 1-13 (1936).
98. Geninatti-Crich S, Alberti D, Szabo I et al. MRI-guided neutron capture therapy by use of a dual gadolinium/boron agent targeted at tumour cells through upregulated lowdensity lipopotein transporters. Chem. Eur. J. 17, 8479-8486 (2011).
99. Hwang KC, Lai PD, Chiang CS, Wang PJ, Yuan CJ. Neutron capture nuclei-containing carbon nanoparticles for destruction of cancer cells. Biomaterials 31, 8419-8425 (2010).
100. Dewi N, Yanagie H, Zhu H et al. Biomed. Pharmacother. 67, 451-457 (2013).
101. Soloway AH, Tjarks W, Barbum BA et al. The chemistry of neutron capture theory. Chem. Rev. 98, 1515-1562 (1988).
102. Butterworth KT, Wyer JA, Brennan-Fournet M et al. Variation if strand break yield for plasmid DNA irradiated with high-Z metal. Radiat. Res. 170(3), 381-387 (2008).
103. Song Y, Xu X, MacRenaris KW, Zhang WQ, Mirkin CA, Meade TJ. Multimodal gadolinium-enriched dna-gold nanoparticle for cellular imaging. Angew. Chem. Int. Ed. Engl. 48, 9143-9147 (2009).
104. Marradi M, Alcantara D, Martinez de le Fuente J, Garcia Martin ML, Cerdan S, Penadès S. Paramagnetic Gd-based gold gluconanoparticles as probes for MRI: tuning relaxivities with sugars. Chem. Commun. 26, 3922-3924 (2009).
105. Brust M, Fink J, Bethell D, Schiffrin DJ, Kiely C. Synthesis and reactions of functionalized gold nanoparticles. J. Chem. Soc. Chem. Commun. 16, 1655-1656 (1995).
106. Mowat P, Mignot A, Rima W et al. In vitro radiosensitizing effects of ultrasmall gadolinium based particles on tumour cells. J. Nanosci. Nanotechnol. 11, 7833-7839 (2011).
107. Miladi I, Aloy MT, Armandy E et al. Combining ultrasmall gadolinium-based nanoparticles with photon irradiation overcomes radioresistance of head and neck suqamous cell carcinoma. Nanomedicine 11(1), 247-257 (2015).
108. Luchette M, Korideck H, Makrigiorgos M, Tillement O, Berbeco R. Radiation dose enhancement of gadolinium-based AGuIX nanoparticles on HeLa cells. Nanomedicine 10(8), 1751-1755 (2014).
109. Porcel E, Tillement O, Lux F et al. Gadolinium-based nanoparticles to improve hadrontherapy performances. Nanomedicine 10(8), 1601-1608 (2014).
110. Le Duc G, Roux S, Paruta-Tuarez A et al. O. Advantages of gadolinium based ultrasmall nanoparticles vs molecular chelates for radiotherapy guided by MRI for glioma treatment. Cancer Nanotechnol. 5, 4 (2014).